IL100386A - Suitable free vaccine against virus - Google Patents

Suitable free vaccine against virus

Info

Publication number: IL100386A
Authority: IL; Israel
Prior art keywords: cell; free; vaccine; virus; viruses
Prior art date: 1990-12-24

Application number

IL10038691A

Other languages

English (en)

Hebrew (he)

Other versions

IL100386A0 (en

Original Assignee

Akzo Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-12-24

Filing date

1991-12-16

Publication date

1995-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8205666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL100386(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-12-16 Application filed by Akzo Nv filed Critical Akzo Nv

1992-09-06 Publication of IL100386A0 publication Critical patent/IL100386A0/xx

1995-07-31 Publication of IL100386A publication Critical patent/IL100386A/en

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 78
241000701047 Gallid alphaherpesvirus 2 Species 0.000 title claims abstract description 10
241000700605 Viruses Species 0.000 claims abstract description 109
208000006758 Marek Disease Diseases 0.000 claims abstract description 95
244000144977 poultry Species 0.000 claims abstract description 12
238000002360 preparation method Methods 0.000 claims description 13
238000000034 method Methods 0.000 claims description 12
238000004113 cell culture Methods 0.000 claims description 7
239000003381 stabilizer Substances 0.000 claims description 7
239000000463 material Substances 0.000 claims description 6
238000005119 centrifugation Methods 0.000 claims description 4
238000004108 freeze drying Methods 0.000 claims description 4
239000000872 buffer Substances 0.000 claims description 3
230000003053 immunization Effects 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
238000001914 filtration Methods 0.000 claims description 2
238000011282 treatment Methods 0.000 claims description 2
229940031416 bivalent vaccine Drugs 0.000 abstract description 6
229940031348 multivalent vaccine Drugs 0.000 abstract description 4
210000004027 cell Anatomy 0.000 description 53
241000271566 Aves Species 0.000 description 18
241000287828 Gallus gallus Species 0.000 description 16
238000002255 vaccination Methods 0.000 description 16
235000013330 chicken meat Nutrition 0.000 description 13
206010028980 Neoplasm Diseases 0.000 description 9
235000013594 poultry meat Nutrition 0.000 description 8
238000011534 incubation Methods 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
239000002609 medium Substances 0.000 description 6
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
102000004142 Trypsin Human genes 0.000 description 5
108090000631 Trypsin Proteins 0.000 description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
230000003902 lesion Effects 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
239000012588 trypsin Substances 0.000 description 5
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000036039 immunity Effects 0.000 description 4
239000000203 mixture Substances 0.000 description 4
230000007170 pathology Effects 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
206010033799 Paralysis Diseases 0.000 description 3
206010058874 Viraemia Diseases 0.000 description 3
-1 albumin or casein) Chemical class 0.000 description 3
230000001461 cytolytic effect Effects 0.000 description 3
231100000517 death Toxicity 0.000 description 3
230000009977 dual effect Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
244000144992 flock Species 0.000 description 3
230000002779 inactivation Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000002458 infectious effect Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
230000001717 pathogenic effect Effects 0.000 description 3
235000021317 phosphate Nutrition 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
238000003860 storage Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
241000711404 Avian avulavirus 1 Species 0.000 description 2
241000711450 Infectious bronchitis virus Species 0.000 description 2
241000702626 Infectious bursal disease virus Species 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
241000286209 Phasianidae Species 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
230000003190 augmentative effect Effects 0.000 description 2
239000007640 basal medium Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000034994 death Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000006196 drop Substances 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
238000010562 histological examination Methods 0.000 description 2
238000000265 homogenisation Methods 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
239000002054 inoculum Substances 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000001161 mammalian embryo Anatomy 0.000 description 2
244000052769 pathogen Species 0.000 description 2
210000000578 peripheral nerve Anatomy 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
239000002356 single layer Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
210000001835 viscera Anatomy 0.000 description 2
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
241000272525 Anas platyrhynchos Species 0.000 description 1
NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241001260012 Bursa Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
206010012305 Demyelination Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000272496 Galliformes Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
208000030289 Lymphoproliferative disease Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001502481 Meleagrid alphaherpesvirus 1 Species 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
229940001007 aluminium phosphate Drugs 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000003837 chick embryo Anatomy 0.000 description 1
238000012258 culturing Methods 0.000 description 1
ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000012447 hatching Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
229940031551 inactivated vaccine Drugs 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
201000001268 lymphoproliferative syndrome Diseases 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000004264 monolayer culture Methods 0.000 description 1
231100001222 nononcogenic Toxicity 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000007918 pathogenicity Effects 0.000 description 1
230000008807 pathological lesion Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
238000012809 post-inoculation Methods 0.000 description 1
238000011886 postmortem examination Methods 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
229960000380 propiolactone Drugs 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
235000017709 saponins Nutrition 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000010257 thawing Methods 0.000 description 1
DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
229940042585 tocopherol acetate Drugs 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
231100000588 tumorigenic Toxicity 0.000 description 1
230000000381 tumorigenic effect Effects 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
230000035899 viability Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/255—Marek's disease virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16361—Methods of inactivation or attenuation
- C12N2710/16364—Methods of inactivation or attenuation by serial passage

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Immunology (AREA)
Microbiology (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Mycology (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

IL10038691A 1990-12-24 1991-12-16 Suitable free vaccine against virus IL100386A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP90314297		1990-12-24

Publications (2)

Publication Number	Publication Date
IL100386A0 IL100386A0 (en)	1992-09-06
IL100386A true IL100386A (en)	1995-07-31

Family

ID=8205666

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10038691A IL100386A (en)	1990-12-24	1991-12-16	Suitable free vaccine against virus

Country Status (17)

Country	Link
US (1)	US5378467A (fr)
EP (1)	EP0496135B1 (fr)
JP (1)	JP3410744B2 (fr)
KR (1)	KR100187317B1 (fr)
CN (1)	CN1034554C (fr)
AT (1)	ATE109007T1 (fr)
CA (1)	CA2058386C (fr)
DE (1)	DE69103130T2 (fr)
DK (1)	DK0496135T3 (fr)
DZ (1)	DZ1550A1 (fr)
ES (1)	ES2061165T3 (fr)
HU (2)	HUT62200A (fr)
IL (1)	IL100386A (fr)
MX (1)	MX9102757A (fr)
NZ (1)	NZ241122A (fr)
SA (1)	SA92120430B1 (fr)
ZA (1)	ZA9110022B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1993023078A1 (fr) *	1992-05-19	1993-11-25	Viktoria Alexeevna Lukina	Vaccin prophylactique contre la maladie de marek chez les oiseaux et son procede de preparation
FR2719056B1 (fr) *	1994-04-20	1996-09-06	Rhone Merieux	Herpesvirus transformés pour exprimer gD in vitro.
IL114501A (en) *	1994-07-14	1999-08-17	Akzo Nobel Nv	Marek's disease virus vaccine
EP0703294A1 (fr) *	1994-07-14	1996-03-27	Akzo Nobel N.V.	Vaccin viral contre la maladie de Marek
US5565202A (en) *	1994-08-12	1996-10-15	The United States Of America As Represented By The Secretary Of Agriculture	Low enhancement serotype 2 vaccine for marek's disease
FR2857671B1 (fr) *	2003-07-18	2007-10-05	Centre Nat Rech Scient	Nouveau procede de culture de keratinocytes et ses applications
DK2384761T3 (da) *	2010-05-07	2013-12-09	Deutsches Krebsforsch	Modificeret gnaverparvovirus, som er i stand til formering og spredning i humane gliomer
WO2019121888A1 (fr)	2017-12-20	2019-06-27	Intervet International B.V.	Diluant perfectionné pour vaccin contre l'alpha-herpèsvirus associé à des cellules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4160024A (en) *	1978-05-01	1979-07-03	Cornell Research Foundation, Inc.	Marek's disease vaccine
US4895718A (en) *	1987-07-10	1990-01-23	The United States Of America, As Represented By The Secretary Of Agriculture	Serotype 2 Marek's disease vaccine
JPS62212326A (ja) *	1987-09-14	1987-09-18	Gen Corp:Kk	マレツク病２価生ワクチンとその製造方法

1991
- 1991-12-16 IL IL10038691A patent/IL100386A/en not_active IP Right Cessation
- 1991-12-19 ZA ZA9110022A patent/ZA9110022B/xx unknown
- 1991-12-20 DE DE69103130T patent/DE69103130T2/de not_active Revoked
- 1991-12-20 AT AT91203365T patent/ATE109007T1/de not_active IP Right Cessation
- 1991-12-20 EP EP91203365A patent/EP0496135B1/fr not_active Revoked
- 1991-12-20 NZ NZ241122A patent/NZ241122A/en not_active IP Right Cessation
- 1991-12-20 ES ES91203365T patent/ES2061165T3/es not_active Expired - Lifetime
- 1991-12-20 DK DK91203365.1T patent/DK0496135T3/da active
- 1991-12-23 CN CN91112829A patent/CN1034554C/zh not_active Expired - Fee Related
- 1991-12-23 HU HU914111A patent/HUT62200A/hu unknown
- 1991-12-23 KR KR1019910023956A patent/KR100187317B1/ko not_active Expired - Fee Related
- 1991-12-23 CA CA002058386A patent/CA2058386C/fr not_active Expired - Fee Related
- 1991-12-23 MX MX9102757A patent/MX9102757A/es unknown
- 1991-12-23 DZ DZ910174A patent/DZ1550A1/fr active
- 1991-12-24 JP JP34156491A patent/JP3410744B2/ja not_active Expired - Fee Related
1992
- 1992-03-18 SA SA92120430A patent/SA92120430B1/ar unknown
1993
- 1993-11-23 US US08/156,967 patent/US5378467A/en not_active Expired - Lifetime
1994
- 1994-12-29 HU HU94P/P00059P patent/HU210344A9/hu unknown

Also Published As

Publication number	Publication date
EP0496135A2 (fr)	1992-07-29
CN1064409A (zh)	1992-09-16
CA2058386C (fr)	2003-02-11
JP3410744B2 (ja)	2003-05-26
HUT62200A (en)	1993-04-28
DZ1550A1 (fr)	2002-02-17
EP0496135B1 (fr)	1994-07-27
KR100187317B1 (ko)	1999-05-01
KR920011520A (ko)	1992-07-24
ATE109007T1 (de)	1994-08-15
MX9102757A (es)	1992-07-01
EP0496135A3 (fr)	1992-08-05
ES2061165T3 (es)	1994-12-01
CN1034554C (zh)	1997-04-16
DE69103130T2 (de)	1994-12-01
HU210344A9 (en)	1995-04-28
ZA9110022B (en)	1992-10-28
IL100386A0 (en)	1992-09-06
HU914111D0 (en)	1992-03-30
DK0496135T3 (da)	1994-11-28
CA2058386A1 (fr)	1992-06-25
NZ241122A (en)	1992-10-28
SA92120430B1 (ar)	2004-05-31
JPH04295433A (ja)	1992-10-20
DE69103130D1 (de)	1994-09-01
US5378467A (en)	1995-01-03

Legal Events

Date	Code	Title
1998-04-05	KB	Patent renewed
2002-02-10	KB	Patent renewed
2006-02-21	KB	Patent renewed
2010-11-30	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
US4530831A (en)	1985-07-23	Infectious Bursal Disease vaccine
US5686287A (en)	1997-11-11	Marek's disease virus vaccine
US3674861A (en)	1972-07-04	Live attenuated marek{40 s disease virus vaccine for poultry
US5378467A (en)	1995-01-03	Cell-free Marek's disease virus vaccine
DK164846B (da)	1992-08-31	Mikrobiologisk ren kultur af en infektioes bronkitisvirusstamme
GB1590448A (en)	1981-06-03	Vaccine and its preparations
US6451321B1 (en)	2002-09-17	IBDV strain in ovo administration
EP1064947B1 (fr)	2007-03-28	Vaccination in ovo contre le virus de la maladie de marek, type 1
KR0127116B1 (ko)	1998-04-01	전염성 점액낭 질병의 예방을 위한 왁찐
EP0760394B1 (fr)	2001-10-10	Vaccin comprenant un virus attenué de la maladie de Newcastle
KR920005661B1 (ko)	1992-07-13	생 조합 백신
AU745477B2 (en)	2002-03-21	Infectious bursitis vaccine
EP0703294A1 (fr)	1996-03-27	Vaccin viral contre la maladie de Marek
EP1161953A2 (fr)	2001-12-12	Souche d'IBDV pour l'administration in ovo
JPWO2000035476A1 (ja)	2002-03-26	１型マレック病ウイルスのインオボワクチネーション
HK1024411B (en)	2006-11-17	Infectious bursitis vaccine